Down-regulated miR-16-2 in peripheral blood is positively correlated with decreased bilateral insula volume in patients with major depressive disorder

Wang, Yu; Yan, Yushun; Wei, Junnian; Yang, Xiao; Wang, Min; Zhao, Liansheng; Dou, Yikai; Du, Yue; Wang, Qiang; Ma, Xiaoyan

doi:10.1016/j.jad.2023.05.068

Cited by 5 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two recently published studies have identified decreased levels of miR-16 in patients diagnosed with MDD, with one study demonstrating an increase in these levels following treatment with sertraline or escitalopram (Ahmadimanesh et al, 2023 [43]; Wang et al, 2023 [44]). Sertraline, but not escitalopram, was found to significantly reduce the levels of miR-132 and miR-124, both of which were elevated in MDD patients (Ahmadimanesh et al, 2023 [43]).…”

Section: Resultsmentioning

confidence: 99%

“…Sertraline, but not escitalopram, was found to significantly reduce the levels of miR-132 and miR-124, both of which were elevated in MDD patients (Ahmadimanesh et al, 2023 [43]). Furthermore, according to Wang et al, 2023 [44], it was observed that miR-16-2 exhibited a negative correlation with both HAMD-17 and HAMA-14 scores (AUC = 0.806, 95% CI: 0.721–0.891) (Wang et al, 2023[44]). Patients displaying higher expression levels of miR-16-2 were more inclined to experience a greater reduction in HAMD-17 scores during short-term follow-up compared to the low-expression group (Wang et al, 2023[44]).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNAs as diagnostic biomarkers and predictors of antidepressant response in major depressive disorder: a systematic review. Running title: miRNAs as biomarkers of MDD

Carneiro,

Guerreiro-Costa,

Lins-Silva

et al. 2024

Preprint

View full text Add to dashboard Cite

Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and pharmacological management of this condition are lacking. MicroRNAs are epigenetic mechanisms that could provide promising MDD biomarkers. Our aim was to summarize the findings and provide validation for the selection and use of specific microRNAs as biomarkers in the diagnosis and treatment of MDD. A systematic review was conducted using the PubMed/MEDLINE, Cochrane, PsycINFO, Embase, and LILACS databases from March to May 2022, with clusters of terms based on microRNA and antidepressant. Studies involving human subjects, animal models, and cell cultures were included, whereas those that evaluated herbal medicines, non-pharmacological therapies, or epigenetic mechanisms other than miRNA were excluded. The review revealed differences in the expression of various microRNAs when considering the time of assessment (before or after antidepressant treatment) and the population studied. However, due to the heterogeneity of the microRNAs investigated, the limited size of the samples, and the wide variety of antidepressants used, few conclusions could be made. Despite the observed heterogeneity, the following microRNAs were determined to be important factors in MDD and the antidepressant response: mir-1202, mir-135, mir-124, and mir-16. The findings indicate the potential for the use of microRNAs as biomarkers for the diagnosis and treatment of MDD; however, more homogeneous studies are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

MicroRNAs as diagnostic biomarkers and predictors of antidepressant response in major depressive disorder: a systematic review. Running title: miRNAs as biomarkers of MDD

Carneiro,

Guerreiro-Costa,

Lins-Silva

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Two recently published studies have identified decreased levels of miR-16 in patients diagnosed with MDD, with one study demonstrating an increase in these levels following treatment with sertraline or escitalopram [ 45 , 46 ]. Sertraline, but not escitalopram, was found to significantly reduce the levels of miR-132 and miR-124, both of which were elevated in MDD patients [ 45 ].…”

Section: Reviewmentioning

confidence: 99%

“…Sertraline, but not escitalopram, was found to significantly reduce the levels of miR-132 and miR-124, both of which were elevated in MDD patients [ 45 ]. Furthermore, according to Wang et al [ 46 ], it was observed that miR-16-2 exhibited a negative correlation with both HAMD-17 and HAMA-14 scores (AUC = 0.806, 95% CI = 0.721-0.891) [ 46 ]. Patients displaying higher expression levels of miR-16-2 were more inclined to experience a greater reduction in HAMD-17 scores during short-term follow-up compared to the low-expression group [ 46 ].…”

Section: Reviewmentioning

confidence: 99%

MicroRNAs as Diagnostic Biomarkers and Predictors of Antidepressant Response in Major Depressive Disorder: A Systematic Review

Carneiro,

Franco Guerreiro-Costa,

Lins-Silva

et al. 2024

Cureus

View full text Add to dashboard Cite

Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and pharmacological management of this condition are lacking. MicroRNAs are epigenetic mechanisms that could provide promising MDD biomarkers. Our aim was to summarize the findings and provide validation for the selection and use of specific microRNAs as biomarkers in the diagnosis and treatment of MDD. A systematic review was conducted using the PubMed/Medline, Cochrane, PsycINFO, Embase, and LILACS databases from March 2022 to November 2023, with clusters of terms based on “microRNA” and “antidepressant”. Studies involving human subjects, animal models, and cell cultures were included, whereas those that evaluated herbal medicines, non-pharmacological therapies, or epigenetic mechanisms other than miRNA were excluded. The review revealed differences in the expression of various microRNAs when considering the time of assessment (before or after antidepressant treatment) and the population studied. However, due to the heterogeneity of the microRNAs investigated, the limited size of the samples, and the wide variety of antidepressants used, few conclusions could be made. Despite the observed heterogeneity, the following microRNAs were determined to be important factors in MDD and the antidepressant response: mir-1202, mir-135, mir-124, and mir-16. The findings indicate the potential for the use of microRNAs as biomarkers for the diagnosis and treatment of MDD; however, more homogeneous studies are needed.

show abstract

“…The mechanisms of miRNA-mediated gene expression include translational repression, mRNA cleavage, post-transcriptional regulation through binding to 3′-untranslated regions (3′-UTRs) of target RNAs [ 9 , 12 , 13 ]. The aberrant expression or dysfunction of miRNAs has been extensively documented to be associated with the pathogenesis and advancement of numerous human diseases, such as diabetes [ 14 ], depressive disorder [ 15 ], rheumatoid arthritis [ 16 ], among others. Of particular significance is the involvement of miRNAs in cancer, with multiple miRNAs identified as either tumor suppressors or tumor promoters [ 4 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

MiRNA-423 rs6505162 and miRNA-6811 rs2292879 SNP associated with lung cancer in Hainan, China

Zhou,

Meng,

et al. 2023

Bioscience Reports

View full text Add to dashboard Cite

Background: MicroRNAs (miRNAs) are known to exert significant influence on various physiological processes and diseases, including cancers. The primary objective of this present study was to examine the impact of eight single-nucleotide polymorphisms (SNPs) in miRNA on the susceptibility to lung cancer (LC) within the Chinese Southern population. Methods: The genotypes of these eight polymorphisms were determined in 132 LC patients and 214 cancer-free controls. Results: In overall analyses, GG genotype of miRNA-6811 rs2292879 polymorphism was significantly correlated with increased risk of LC (GG vs. AA, adjusted OR = 5.10, 95% CI = 1.02–25.43, P=0.047), yet the genotype frequencies of rs2292879 SNP in controls did not met the Hardy–Weinberg equilibrium (HWE) (P=0.001) in present study. Stratified analyses by smoking revealed that miRNA-423 rs6505162 variants significantly decreased the LC risk in heterozygous (CA vs. CC, adjusted OR = 0.14, 95% CI = 0.03–0.81, P=0.028) and recessive (AA vs. CA + CC, adjusted OR = 0.17, 95% CI = 0.03–0.90, P=0.038) genetic models in smoking population. However, miRNA-196A2 rs11614913, miRNA-196A2 rs12304647, miRNA-146A rs2910164, miRNA-16-1 rs1022960, miRNA-608 rs4919510, and miRNA-27a rs895819 polymorphisms were not significantly associated with LC. Conclusion: The findings of our study indicate a potential decrease in LC risk among smokers with the miRNA-423 rs6505162 variants, while an increase in risk is associated with miRNA-6811 rs2292879 polymorphisms in the population of Southern Chinese. However, further well-designed research is necessary to fully understand the precise impact of these two SNPs on the development of LC.

show abstract

Down-regulated miR-16-2 in peripheral blood is positively correlated with decreased bilateral insula volume in patients with major depressive disorder

Cited by 5 publications

References 41 publications

MicroRNAs as diagnostic biomarkers and predictors of antidepressant response in major depressive disorder: a systematic review. Running title: miRNAs as biomarkers of MDD

MicroRNAs as diagnostic biomarkers and predictors of antidepressant response in major depressive disorder: a systematic review. Running title: miRNAs as biomarkers of MDD

MicroRNAs as Diagnostic Biomarkers and Predictors of Antidepressant Response in Major Depressive Disorder: A Systematic Review

MiRNA-423 rs6505162 and miRNA-6811 rs2292879 SNP associated with lung cancer in Hainan, China

Contact Info

Product

Resources

About